

type of report	<b>Current report</b>
number	19/2014
company	PHARMENA

**Information on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA**

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13<sup>th</sup> April 2012) and the communication on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA (published in current report no. 85/2013 of 27<sup>th</sup> December 2013), the Management of Board PHARMENA S.A. informs that as of 31<sup>st</sup> March 2014, 15 patients were included to phase II clinical trials over anti-atherosclerosis medicinal product 1-MNA.

The aim of the phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product will consist in establishing the effective dose of the medicinal product and confirming the lack of side effects in humans in the tested doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator (7<sup>th</sup> October 2013). Montreal Heart Institute serves as the supervisory institution, and currently 14 clinics participate in the trials.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world-renowned Institute, that has introduced many innovatory solutions nationally and worldwide. For more information, see [www.icm-mhi.org](http://www.icm-mhi.org).

Phase II clinical trial ("Proof of Concept") are financed from funds raised in issue of series D shares.

Subsequent current reports issued by the Company will inform on progress of research and trials of the 1-MNA innovative anti-atherosclerotic medicinal product.

This information is made public due to the fact that conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

**Representatives of the company:**

- Konrad Palka – President of the Board
- Marzena Wieczorkowska – Vice President of the Board